natgillin/translations-raw huggingface dataset:
The company will use specific databases to monitor ACOMPLIA's side effects, especially those linked to the nervous system. 
Podjetje bo uporabilo specifične zbirke podatkov za spremljanje neželenih učinkov zdravila ACOMPLIA, zlasti tistih, povezanih z živčnim sistemom.
Therefore, ACOMPLIA is not recommended as an aid for smoking cessation 
Zdravila ACOMPLIA torej ni moč priporočiti kot pomoč pri prenehanju kajenja.
Patients who experience symptoms of depression should speak to their doctor and may need to stop treatment. 
Bolniki, pri katerih se pojavi depresija, se morajo pogovoriti z zdravnikom, zdravljenje pa bo morda potrebno prekiniti.
What benefit has ACOMPLIA shown during the studies? 
Kakšne koristi je zdravilo ACOMPLIA izkazalo med raziskavami?
The company decided to withdraw its application for smoking cessation. 
Podjetje se je odločilo, da umakne svojo vlogo za uporabo zdravila pri prenehanju kajenja.
The medicine should not be used in patients who have severe problems with their liver or their kidneys. 
Zdravila ne smejo jemati osebe, ki imajo hude težave z jetri ali ledvicami.
The active substance in ACOMPLIA, rimonabant, is a cannabinoid receptor antagonist. 
Zdravilna učinkovina v zdravilu ACOMPLIA, rimonabant, je antagonist kanabinoidnih receptorjev.
Caution should be used when taking ACOMPLIA with some medicines, such as ketoconazole or itraconazole (anti-fungal medicines), ritonavir (used in HIV infection), or telithromycin or clarithromycin (antibiotics). 
Pri sočasnem jemanju zdravila ACOMPLIA in nekaterih drugih zdravil, kot so ketokonazol ali itrakonazol (zdravili proti glivicam), ritonavir (ki se uporablja pri okužbi s HIV), telitromicin ali klaritromicin (antibiotika) je potrebna previdnost.
After one year, all patients who received ACOMPLIA lost more weight than those who received placebo: they lost on average 4.9 kg more than placebo, except in the study in diabetic patients, where the difference in the weight loss was 3.9 kg. 
Po enem letu se je pri bolnikih, ki so prejemali zdravilo ACOMPLIA telesna masa zmanjšala bolj kot pri tistih, ki so prejemali placebo: povprečno so izgubili 4,9 kg več kot s placebom, razen v študiji z diabetičnimi bolniki, kjer je bila razlika v zmanjšanju telesne mase 3,9 kg.
The Committee recommended that ACOMPLIA be given marketing authorisation. 
Odbor je priporočil odobritev dovoljenja za promet z zdravilom ACOMPLIA.
The company that makes ACOMPLIA will put in place a programme to ensure that the medicine is used in patients who need it for health, rather than for cosmetic reasons, by providing educational packs for patients and doctors, and to monitor how the medicine is used. 
Podjetje, ki izdeluje zdravilo ACOMPLIA, bo pripravilo program z izobraževalnim gradivom za bolnike in zdravnike za zagotovitev, da se zdravilo uporablja pri bolnikih, ki ga potrebujejo zaradi zdravja in ne iz kozmetičnih razlogov ter bo nadzorovalo njegovo uporabo.
ACOMPLIA is a medicine containing the active substance rimonabant. 
ACOMPLIA je zdravilo, ki vsebuje zdravilno učinkovino rimonabant.
Why has ACOMPLIA been approved? 
Zakaj je bilo zdravilo ACOMPLIA odobreno?
What is the risk associated with ACOMPLIA? 
Kakšna tveganja so povezana z zdravilom ACOMPLIA?
• who are obese (very overweight) with a body mass index (BMI) greater than or equal to 30 kg/m², 
• so debeli (z zelo prekomerno telesno maso) s indeksom telesne mase (BMI) večjim ali enakim 30
ACOMPLIA is used together with diet and exercise to treat adult patients: 
ACOMPLIA se kot dodatek k dieti in telesni dejavnosti uporablja za zdravljenje odraslih bolnikov, ki:
The Committee for Medicinal products for Human Use (CHMP) concluded that ACOMPLIA had shown its effectiveness in weight reduction in obese or overweight patients with associated risk factors. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je sklenil, da je zdravilo ACOMPLIA izkazalo učinkovitost pri zmanjšanju telesne mase pri debelih bolnikih in bolnikih s čezmerno telesno maso, pri katerih obstajajo dodatni dejavniki tveganja.
ACOMPLIA should not be used in patients who may be hypersensitive (allergic) to rimonabant or any of the other ingredients, or in women who are breast feeding. 
Zdravila ACOMPLIA ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) rimonabant ali katero koli drugo sestavino zdravila ter ženske, ki dojijo.
For the full list of all side effects reported with ACOMPLIA, see the Package Leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila ACOMPLIA, glejte Navodilo za uporabo.
During the studies, the most common side effects with ACOMPLIA (seen in more than 1 patient in 10) were nausea (feeling sick) and infections of the upper respiratory tract. 
Neželeni učinki zdravila ACOMPLIA, ki so bili med študijami najpogosteje opaženi (pri več kot 1 od 10 bolnikov) so bili navzeja (občutek slabosti) in okužbe zgornjih dihal.
studies compared the effect of ACOMPLIA with that of a placebo (a dummy treatment) on weight loss over one to two years. 
V študijah so primerjali učinek zdravila ACOMPLIA z učinkom placeba (zdravila brez zdravilne učinkovine) na zmanjšanje telesne mase v enem do dveh let.
The Committee decided that ACOMPLIA's benefits are greater than its risks when used, in addition to diet and exercise, to treat obese patients and overweight patients with risk factors such as type 2 diabetes or dyslipidaemia. 
Odločil je, da so koristi zdravila ACOMPLIA, kadar se uporablja kot dodatek k dieti in telesni dejavnosti pri zdravljenju debelih bolnikov in bolnikov s čezmerno telesno maso z dodatnimi dejavniki tveganja kot so diabetes tipa 2 ali dislipidemija, večje od z njim povezanih tveganj.
Four studies of ACOMPLIA in overweight and obese patients were carried out, involving almost 7,000 patients, whose weight at the start of the studies was on average 94 to 104 kg. One study looked more particularly at patients with abnormal levels of blood fat, and one at patients with type 2 diabetes. 
Zdravilo ACOMPLIA je bilo raziskano v štirih študijah, v katerih je sodelovalo skoraj 7000 debelih bolnikov in bolnikov s čezmerno telesno maso, katerih teža je bila na začetku študij povprečno med 94 in 104 kg.
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) ACOMPLIA EPAR summary for the public 
Povzetek EPAR za javnost
How has ACOMPLIA been studied? 
Kako je bilo zdravilo ACOMPLIA raziskano?
What is ACOMPLIA used for? 
Za kaj se zdravilo ACOMPLIA uporablja?
Four studies of ACOMPLIA as a help to stop smoking were also carried out in over 7,000 patients, comparing it with placebo, and measuring the effect of the medicine given for 10 weeks (one year in one of the studies) on smoking cessation, and on relapses in the following year. 
Zdravilo so primerjali s placebom in merili učinek zdravila, uporabljanega 10 tednov (eno leto v eni od študij), na prenehanje kajenja ter na ponoven začetek kajenja v naslednjem letu.
The full EPAR for ACOMPLIA can be found here. 
Celotno Evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo ACOMPLIA je na voljo tukaj.
It must also not be used in patients with ongoing major depression or who are being treated with antidepressants, since it can increase the risk of depression, including thoughts about suicide in a small minority of patients. 
Zdravilo lahko poveča tveganje za depresijo in pri majhnem številu bolnikov povzroči samomorilne misli, zato se ne sme uporabljati pri bolnikih s trenutno potekajočo veliko depresivno motnjo ali bolnikih, ki se zdravijo z antidepresivi.
How is ACOMPLIA used? 
Kako se zdravilo ACOMPLIA uporablja?
• who are overweight (with a BMI greater than or equal to 27 kg/m²) and also have other risk factors, 
• imajo čezmerno telesno maso (imajo BMI večji ali enak 27 kg/m²) in pri katerih obstajajo dodatni dejavniki tveganja, kot so na primer diabetes tipa 2 ali dislipidemija (nenormalne ravni maščobe v krvi).
What is ACOMPLIA? 
Kaj je zdravilo ACOMPLIA?
How does ACOMPLIA work? 
Kako zdravilo ACOMPLIA deluje?
The studies lasted 12 weeks. 
Študije so trajale 12 tednov.
The European Commission granted a marketing authorisation valid throughout the European Union for Levitra on 6 March 2003. 
Evropska komisija je dovoljenje za promet z zdravilom Levitra, veljavno po vsej Evropski uniji, izdala 6. marca 2003.
What measures are being taken to ensure the safe and effective use of Levitra? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Levitra?
In all of the studies, the main measure of effectiveness was the ability to get and maintain an erection. 
Glavno merilo učinkovitosti v vseh študijah je bila sposobnost doseči in obdržati erekcijo.
What benefit has Levitra shown during the studies? 
Kakšne koristi je zdravilo Levitra izkazalo med študijami?
The full EPAR for Levitra can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Levitra je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
The most common side effect with Levitra (seen in more than 1 patient in 10) is headache. 
Najpogostejši neželeni učinek zdravila Levitra (opažen pri več kot 1 bolniku od 10) je glavobol.
The recommended dose of Levitra is 10 mg, taken about 25 to 60 minutes before sexual activity. 
Priporočeni odmerek zdravila Levitra je 10 mg, ki se vzame približno od 25 do 60 minut pred spolnim odnosom.
Because Levitra has not been studied in the following group patients, they must not use the medicine: 
Ker zdravilo Levitra pri naslednjih skupinah bolnikov ni bilo raziskano, zdravila ne smejo jemati:
The maximum recommended dosing frequency is one film-coated tablet or orodispersible tablet per day. 
Največja priporočena pogostnost odmerjanja je ena filmsko obložena tableta ali orodisperzibilna tableta na dan.
The orodispersible tablets must be taken without liquid. 
Orodisperzibilne tablete je treba vzeti brez tekočine.
A risk management plan has been developed to ensure that Levitra is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Levitra je bil pripravljen načrt obvladovanja tveganj.
What is the risk associated with Levitra? 
Kakšna tveganja so povezana z zdravilom Levitra?
For more information about treatment with Levitra, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Levitra preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The CHMP decided that Levitra's benefits are greater than its risks and recommended that it be given marketing authorisation. 
Odbor CHMP je zaključil, da so koristi zdravila Levitra večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
This document is a summary of the European public assessment report (EPAR) for Levitra. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Levitra.
Other information about Levitra: 
Druge informacije o zdravilu Levitra
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Levitra, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
• patients with unstable angina and hereditary eye problems known as ‘retinal degenerative disorders'. 
• bolniki z nestabilno angino pektoris in dednimi očesnimi težavami, znanimi kot „retinalna degenerativna obolenja“.
Why has Levitra been approved? 
Zakaj je bilo zdravilo Levitra odobreno?
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Levitra. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Levitra is a medicine that contains the active substance vardenafil. 
Levitra je zdravilo, ki vsebuje zdravilno učinkovino vardenafil.
Two additional main studies compared orodispersible tablets with placebo in 701 men aged 21 to 84 years 
V dveh dodatnih glavnih študijah so orodisperzibilne tablete pri 701 moškem, starem od 21 do 84 let, primerjali s placebom.
The active ingredient of Levitra, vardenafil, belongs to a group of medicines called phosphodiesterase type 5 (PDE5) inhibitors. 
Zdravilna učinkovina v zdravilu Levitra, vardenafil, spada v skupino zdravil, imenovanih zaviralci fosfodiesteraze tipa 5 (PDE5).
Levitra must not be used in people who are hypersensitive (allergic) to vardenafil or any of the other ingredients. 
Zdravila Levitra ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) vardenafil ali katero koli drugo sestavino zdravila.
Levitra tablets and orodispersible tablets were significantly more effective than placebo for all measures in all of the studies. 
Zdravilo Levitra je bilo v obliki tablet in orodisperzibilnih tablet v vseh študijah in ob vseh uporabljenih merilih znatno učinkovitejše od placeba.
During normal sexual stimulation, cGMP is produced in the penis, where it causes the muscle in the spongy tissue of the penis (the corpora cavernosa) to relax. 
Med normalnim spolnim vzburjenjem se cGMP tvori v penisu, v katerem povzroči, da se gobasto tkivo penisa (corpora cavernosa) sprosti.
Levitra must not be taken with ketoconazole and itraconazole (used to treat fungal infections) in men over 75 years of age, or with medicines called ‘HIV protease inhibitors' such as ritonavir or indinavir (used to treat HIV infection). 
Zdravilo Levitra se ne sme jemati s ketokonazolom in itrakonazolom (zdravili za zdravljenje glivičnih okužb) pri moških, starejših od 75 let, ali zdravili, imenovanimi „zaviralci proteaz HIV“, kot na primer ritonavir ali indinavir (zdravili za zdravljenje okužbe z virusom HIV).
Levitra tablets were compared with placebo (a dummy treatment) in four main studies including a total of 2,431 men with erectile dysfunction aged 20 to 83 years. 
Zdravilo Levitra so primerjali s placebom (zdravilom brez zdravilne učinkovine) v štirih glavnih študijah, v katerih je sodelovalo skupno 2 431 moških z erektilno disfunkcijo, starih od 20 do 83 let.
Levitra is used to treat adult men (aged 18 years or over) with erectile dysfunction (sometimes called impotence), when they cannot get or keep a hard penis (erection) sufficient for satisfactory sexual activity. 
Zdravilo Levitra se uporablja za zdravljenje erektilne disfunkcije (imenovane tudi impotenca) pri odraslih moških (starejših od 18 let), kadar ne zmorejo doseči ali ohraniti takšne erekcije penisa, ki omogoča zadovoljivo spolno dejavnost.
It must also not be used in patients who have ever had loss of vision because of a problem with blood flow to the nerve in the eye (non-arteritic anterior ischemic optic neuropathy or NAION). 
Prav tako ga ne smejo jemati bolniki, ki so kadar koli imeli težave z vidom zaradi dotoka krvi v očesni živec (nearteritična anteriorna ishemična optična nevropatija - NAION).
In addition, Levitra must not be taken with medicines known as guanylate cyclase stimulators, including riociguat (used to treat pulmonary hypertension [high blood pressure in the lungs]). 
Poleg tega se ne jemati skupaj z zdravili, imenovanimi spodbujevalci gvanilat ciklaze, vključno z riocigvatom (zdravilom za zdravljenje pljučne hipertenzije, tj. visokega krvnega tlaka v pljučih).
Levitra must not be taken with nitrates (medicines used to treat angina). 
Zdravilo Levitra se ne sme jemati skupaj z nitrati (zdravili za zdravljenje angine pektoris).
The dose of the film-coated tablets may be increased to a maximum of 20 mg or decreased to 5 mg, depending on the effectiveness of treatment and any side effects. 
Odmerek filmsko obloženih tablet se lahko glede na učinkovitost zdravljenja in morebitne neželene učinke poveča na 20 mg ali zmanjša na 5 mg.
For the full list of all side effects reported with Levitra, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Levitra, glejte navodilo za uporabo.
One of these studies was carried out in diabetic men and another in men who had had their prostate gland removed. 
V eno študijo so bili vključeni moški s sladkorno boleznijo, v drugo pa bolniki, ki jim je bila odstranjena prostata.
The dose may need to be adjusted in patients taking other medicines that block enzymes that break down Levitra. 
Pri osebah, ki jemljejo druga zdravila, ki zavirajo encime, ki razgrajujejo zdravilo Levitra, bo odmerek morda treba prilagoditi.
By blocking the breakdown of cGMP, Levitra restores erectile function. 
Zdravilo Levitra z zaviranjem razgradnje cGMP ponovno vzpostavi erektilno funkcijo.
How does Levitra work? 
Kako zdravilo Levitra deluje?
What is Levitra used for? 
Za kaj se zdravilo Levitra uporablja?
A starting dose of 5 mg should be considered for patients with mild and moderate liver problems or severe kidney problems. 
Bolniki z blagimi ali zmernimi težavami z jetri ali resnimi motnjami v delovanju ledvic naj začnejo s 5-miligramskim odmerkom.
How has Levitra been studied? 
Kako je bilo zdravilo Levitra raziskano?
How is Levitra used? 
Kako se zdravilo Levitra uporablja?
What is Levitra? 
Kaj je zdravilo Levitra?
For Levitra to be effective, sexual stimulation is required. 
Zdravilo Levitra je učinkovito le ob spolnem vzburjenju.
If Levitra film-coated tablets are taken with a high fat meal, the onset of activity may be delayed. 
Zdravilo Levitra v obliki filmsko obloženih tablet lahko začne učinkovati pozneje, če se zaužije s hrano, ki vsebuje veliko maščob.
Monday Tuesday Wednesday Thursday Friday Saturday Sunday 
DRUGI PODATKI ponedeljek torek sreda četrtek petek sobota nedelja
- if the patient is less than 2 years of age. 
- če je bolnik mlajši od 2 let.
Via Provinciale Schito 131 80058 Torre Annunziata (NA) Italy 
Via Provinciale Schito 131 80058 Torre Annunziata (NA) Italija
Some side effects can be serious (frequency not known): 
Nekateri neželeni učinki so lahko resni (pogostnost neznana):
The AUC is 50% higher in elderly (> 65 years) than in young subjects. 
AUC je pri starejših (> 65 let) 50 % večja kot pri mladih osebah.
The mean half-life is about 40 hours (range 34-41 hours). 
Izločanje Povprečen razpolovni čas je približno 40 ur (v okviru 34 - 41 ur).
Rasilez with food and drink 
Zdravilo Rasilez skupaj s hrano in pijačo
Date of latest renewal: 22 May 2017 
Datum prve odobritve: 22. avgust 2007 Datum zadnjega podaljšanja: 22. maj 2017
You may need to stop Rasilez. 
Morda boste morali prenehati z jemanjem zdravila Rasilez.
Your doctor will normally advise you to stop taking this medicine before you become pregnant and will advise you to take another medicine instead of this medicine. 
Zdravnik vam bo praviloma svetoval, da prenehate z jemanjem tega zdravila še preden zanosite in vam bo svetoval jemanje drugega zdravila namesto tega.
Palpitations, oedema peripheral 
palpitacije, periferni edemi
It is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy. 
Jemanje tega zdravila med zgodnjo nosečnostjo ni priporočljivo, ko pa ste noseči več kot 3 mesece, ga ne smete jemati, ker lahko uporaba po tretjem mesecu nosečnosti povzroči resno škodo vašemu otroku.
If you have severe and persistent diarrhoea you should stop taking Rasilez. 
Če imate hudo in trdovratno drisko, morate prenehati z jemanjem zdravila Rasilez.
Your doctor may prescribe this medicine together with other medicines used to treat high blood pressure. 
Zdravnik vam lahko predpiše to zdravilo skupaj z drugimi zdravili za zdravljenje visokega krvnega tlaka.
This medicine must not be used in babies from birth to less than 2 years of age. 
Tega zdravila se nikakor ne sme uporabljati pri dojenčkih od rojstva do dopolnjenega 2. leta starosti,
Do not take this medicine if you are pregnant (see section “Do not take Rasilez”). 
Če ste noseči, ne jemljite tega zdravila (glejte poglavje "Ne jemljite zdravila Rasilez").
Other medicines and Rasilez 
Druga zdravila in zdravilo Rasilez
See also section “Do not take Rasilez”. 
Glejte tudi poglavje »Ne jemljite zdravila Rasilez«.
The European Medicines Agency has deferred the obligation to submit the results of studies with aliskiren in one or more subsets of the paediatric population in hypertension (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je začasno odložila zahtevo za predložitev rezultatov študij z aliskirenom za eno ali več podskupin pediatrične populacije pri hipertenziji (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
angioedema without any known cause. 
prirojeni angioedem; angioedem brez znanega vzroka;
Fruit juice and drinks containing plant extracts 
Sadni sok in napitki, ki vsebujejo rastlinske izvlečke
If you forget to take Rasilez 
Če ste pozabili vzeti zdravilo Rasilez
In experimental animals, it has been shown that P-gp is a major determinant of Rasilez bioavailability. 
Na poskusnih živalih se je pokazalo, da je P-gp glavna determinanta biološke uporabnosti zdravila Rasilez.
When driving vehicles or using machines it must be borne in mind that dizziness or drowsiness may occasionally occur when taking Rasilez. 
Pri vožnji in uporabi strojev je treba upoštevati, da lahko med jemanjem zdravila Rasilez občasno pride do omotice ali zaspanosti.
What Rasilez is and what it is used for What you need to know before you take Rasilez How to take Rasilez 
Kaj je zdravilo Rasilez in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Rasilez Kako jemati zdravilo Rasilez
There are no clinical data on fertility. 
Kliničnih podatkov o vplivu na plodnost ni.
**Including one case of ‘liver failure fulminant' reported in the post-marketing experience, for which a causal relationship with aliskiren cannot be excluded. 
**vključno z enim primerom “fulminantne odpovedi jeter”, o katerem so poročali med izkušnjami v obdobju trženja zdravila in pri katerem vzročne povezanosti z aliskirenom ni mogoče izključiti
Aliskiren should not be used during breast-feeding. 
Aliskirena se ne sme uporabljati v času dojenja.
Nausea, vomiting 
navzea, bruhanje
Serious adverse reactions include anaphylactic reaction and angioedema which have been reported in post-marketing experience and may occur rarely (less than 1 case per 1,000 patients). 
Resni neželeni učinki vključujejo anafilaktično reakcijo in angioedem, o katerih so poročali med izkušnjami v obdobju trženja zdravila, pojavljata pa se redko (manj kot 1 primer na 1.000 bolnikov).
Use of Rasilez is not recommended in this population. 
Zdravila Rasilez ne uporabljajte pri tej populaciji.
If pregnancy is detected during therapy, treatment should be discontinued accordingly. 
V primeru, da se med zdravljenjem izkaže, da je ženska noseča, je treba zdravljenje v skladu s tem prekiniti.
In the event of severe and persistent diarrhoea, Rasilez therapy should be stopped (see section 4.8). 
V primeru hude ali persistentne driske je treba zdravljenje z zdravilom Rasilez prekiniti (glejte poglavje 4.8).
Co-administration of aliskiren with either metformin (↓28%), amlodipine (↑29%) or cimetidine 
Ob sočasni uporabi aliskirena z metforminom (↓28 %), amlodipinom (↑29 %) ali s cimetidinom
If anaphylactic reactions or angioedema occur, treatment should be promptly discontinued and appropriate therapy and monitoring provided until complete and sustained resolution of signs and symptoms has occurred. 
Če pride do anafilaktične reakcije ali angioedema, je treba zdravljenje z aliskirenom takoj prekiniti in poskrbeti za ustrezno zdravljenje in spremljanje bolnika, dokler znaki in simptomi niso v celoti in trajno odpravljeni.